Omentin‑1 induces osteoblast viability and differentiation via the TGF‑β/Smad signaling pathway in osteoporosis

Tang,Cuisong; Liang,Dengpan; Qiu,Yuyou; Zhu,Jingqi; Tang,Guangyu

doi:10.3892/mmr.2022.12648

Omentin‑1 induces osteoblast viability and differentiation via the TGF‑β/Smad signaling pathway in osteoporosis

Authors:
- Cuisong Tang
- Dengpan Liang
- Yuyou Qiu
- Jingqi Zhu
- Guangyu Tang
View Affiliations

Affiliations: Department of Radiology, Clinical Medical College of Shanghai Tenth People's Hospital of Nanjing Medical University, Shanghai 200072, P.R. China, Department of Cardiology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China, Department of Radiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Radiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Radiology, Clinical Medical College of Shanghai Tenth People's Hospital of Nanjing Medical University, Shanghai 200072, P.R. China
Published online on: February 17, 2022 https://doi.org/10.3892/mmr.2022.12648
Article Number: 132
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteoporosis is a bone‑related disease that results from impaired bone formation and excessive bone resorption. The potential value of adipokines has been investigated previously, due to their influence on osteogenesis. However, the osteogenic effects induced by omentin‑1 remain unclear. The aim of the present study was to determine the regulatory effects of omentin‑1 on osteoblast viability and differentiation, as well as to explore the underlying molecular mechanism. The present study investigated the effects of omentin‑1 on the viability and differentiation of mouse pre‑osteoblast cells (MC3T3‑E1) using quantitative and qualitative measures. A Cell Counting Kit‑8 assay was used to assess the viability of MC3T3‑E1 cells following treatment with different doses of omentin‑1. Omentin‑1 and bone morphogenetic protein (BMP) inhibitor were added to osteogenic induction mediums in different ways to assess their effect. The alkaline phosphatase (ALP) activity and Alizarin Red S (ARS) staining of MC3T3‑E1 cells treated with omentin‑1 and/or BMP inhibitor were used to examine the effects of omentin‑1 on differentiation and mineralization. Western blotting was used to further explore its potential mechanism, and to study the role of omentin‑1 on the viability and differentiation of osteoblasts. The results showed that omentin‑1 altered the viability of MC3T3‑E1 cells in a dose‑dependent manner. Omentin‑1 treatment significantly increased the expression of members of the TGF‑β/Smad signaling pathway. In the omentin‑1 group, the ALP activity of the MC3T3‑E1 cells was increased, and the ARS staining area was also increased. The mRNA and protein expression levels of BMP2, Runt‑related transcription factor 2, collagen1, osteopontin, osteocalcin and osterix in the omentin‑1 group were also significantly upregulated. All these effects were reversed following treatment with SIS3 HCl. These results demonstrated that omentin‑1 can significantly promote osteoblast viability and differentiation via the TGF‑β/Smad signaling pathway, thereby promoting bone formation and preventing osteoporosis.

View Figures

View References

1	Miller PD: Management of severe osteoporosis. Expert Opin Pharmacother. 17:473–488. 2016. View Article : Google Scholar : PubMed/NCBI
2	Noh JY, Yang Y and Jung H: Molecular mechanisms and emerging therapeutics for osteoporosis. Int J Mol Sci. 21:76232020. View Article : Google Scholar : PubMed/NCBI
3	Clark S: Osteoporosis-the disease of the 21st century? Lancet. 359:17142002. View Article : Google Scholar : PubMed/NCBI
4	Cooper C: Epidemiology of osteoporosis. Osteoporos Int. 9 (Suppl 2):S2–S8. 1999. View Article : Google Scholar : PubMed/NCBI
5	Johnell O and Kanis J: Epidemiology of osteoporotic fractures. Osteoporos Int. 16 (Suppl 2):S3–S7. 2005. View Article : Google Scholar : PubMed/NCBI
6	Straka M, Straka-Trapezanlidis M, Deglovic J and Varga I: Periodontitis and osteoporosis. Neuro Endocrinol Lett. 36:401–406. 2015.PubMed/NCBI
7	Kurra S, Fink DA and Siris ES: Osteoporosis-associated fracture and diabetes. Endocrinol Metab Clin North Am. 43:233–243. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lane NE: Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 194 (Suppl 2):S3–S11. 2006. View Article : Google Scholar : PubMed/NCBI
9	Baccaro LF, Conde DM, Costa-Paiva L and Pinto-Neto AM: The epidemiology and management of postmenopausal osteoporosis: A viewpoint from Brazil. Clin Interv Aging. 10:583–591. 2015. View Article : Google Scholar : PubMed/NCBI
10	Lane JM, Russell L and Khan SN: Osteoporosis. Clin Orthop Relat Res. 372:139–150. 2000. View Article : Google Scholar : PubMed/NCBI
11	Chen X, Wang Z, Duan N, Zhu G, Schwarz EM and Xie C: Osteoblast-osteoclast interactions. Connect Tissue Res. 59:99–107. 2018. View Article : Google Scholar : PubMed/NCBI
12	Jayakumar P and Di Silvio L: Osteoblasts in bone tissue engineering. Proc Inst Mech Eng H. 224:1415–1440. 2010. View Article : Google Scholar : PubMed/NCBI
13	Malhotra A and Habibovic P: Calcium phosphates and angiogenesis: Implications and advances for bone regeneration. Trends Biotechnol. 34:983–992. 2016. View Article : Google Scholar : PubMed/NCBI
14	Leijten J, Chai YC, Papantoniou I, Geris L, Schrooten J and Luyten FP: Cell based advanced therapeutic medicinal products for bone repair: Keep it simple? Adv Drug Deliv Rev. 84:30–44. 2015. View Article : Google Scholar : PubMed/NCBI
15	Wei DX, Dao JW and Chen GQ: A Micro-Ark for Cells: Highly open porous polyhydroxyalkanoate microspheres as injectable scaffolds for tissue regeneration. Adv Mater. 30:e18022732018. View Article : Google Scholar : PubMed/NCBI
16	Shen X, Zhang Y, Gu Y, Xu Y, Liu Y, Li B and Chen L: Sequential and sustained release of SDF-1 and BMP-2 from silk fibroin-nanohydroxyapatite scaffold for the enhancement of bone regeneration. Biomaterials. 106:205–216. 2016. View Article : Google Scholar : PubMed/NCBI
17	Cahill KS, Chi JH, Day A and Claus EB: Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 302:58–66. 2009. View Article : Google Scholar : PubMed/NCBI
18	Skovrlj B, Koehler SM, Anderson PA, Qureshi SA, Hecht AC, Iatridis JC and Cho SK: Association between BMP-2 and carcinogenicity. Spine (Phila Pa 1976). 40:1862–1871. 2015. View Article : Google Scholar : PubMed/NCBI
19	Xu C, Su P, Chen X, Meng Y, Yu W, Xiang AP and Wang Y: Biocompatibility and osteogenesis of biomimetic Bioglass-Collagen-Phosphatidylserine composite scaffolds for bone tissue engineering. Biomaterials. 32:1051–1058. 2011. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Fan W, Ma Z, Wu C, Fang W, Liu G and Xiao Y: The effects of pore architecture in silk fibroin scaffolds on the growth and differentiation of mesenchymal stem cells expressing BMP7. Acta Biomater. 6:3021–3028. 2010. View Article : Google Scholar : PubMed/NCBI
21	Holzwarth JM and Ma PX: Biomimetic nanofibrous scaffolds for bone tissue engineering. Biomaterials. 32:9622–9629. 2011. View Article : Google Scholar : PubMed/NCBI
22	Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J and Buchler C: Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 1732:96–102. 2005. View Article : Google Scholar : PubMed/NCBI
23	Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC and Gong DW: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 290:E1253–E1261. 2006. View Article : Google Scholar : PubMed/NCBI
24	Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M and Hara Y: Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun. 408:339–343. 2011. View Article : Google Scholar : PubMed/NCBI
25	Yamawaki H, Tsubaki N, Mukohda M, Okada M and Hara Y: Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 393:668–672. 2010. View Article : Google Scholar : PubMed/NCBI
26	Duan XY, Xie PL, Ma YL and Tang SY: Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids. 41:1223–1231. 2011. View Article : Google Scholar : PubMed/NCBI
27	de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, et al: Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 56:1655–1661. 2007. View Article : Google Scholar : PubMed/NCBI
28	Tohidi M, Akbarzadeh S, Larijani B, Kalantarhormozi M, Ostovar A, Assadi M, Vahdat K, Farrokhnia M, Sanjdideh Z, Amirinejad R and Nabipour I: Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women. Bone. 51:876–881. 2012. View Article : Google Scholar : PubMed/NCBI
29	Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G and Fernández-Real JM: Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 7:272010. View Article : Google Scholar : PubMed/NCBI
30	Xie H, Xie PL, Wu XP, Chen SM, Zhou HD, Yuan LQ, Sheng ZF, Tang SY, Luo XH and Liao EY: Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. Cardiovasc Res. 92:296–306. 2011. View Article : Google Scholar : PubMed/NCBI
31	Wang J, Wang M, Chen F, Wei Y, Chen X, Zhou Y, Yang X, Zhu X, Tu C and Zhang X: Nano-hydroxyapatite coating promotes porous calcium phosphate ceramic-induced osteogenesis via BMP/Smad signaling pathway. Int J Nanomedicine. 14:7987–8000. 2019. View Article : Google Scholar : PubMed/NCBI
32	Liu Z, Yu Z, Chang H, Wang Y, Xiang H, Zhang X and Yu B: Strontium-containing α-calcium sulfate hemihydrate promotes bone repair via the TGF-β/Smad signaling pathway. Mol Med Rep. 20:3555–3564. 2019.PubMed/NCBI
33	Wang QL, Li HF, Wang DP, Liu ZY, Xiao WW, Xu LL and Yu S: Effect of GGCX on the differentiation function of osteoporosis bone marrow mesenchymal stem cells through regulating TGFβ/smad signaling pathway. Eur Rev Med Pharmacol Sci. 23:7224–7231. 2019.PubMed/NCBI
34	Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, Han BH, Kim MS, Shin CS and Kim SY: Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone. 37:359–369. 2005. View Article : Google Scholar : PubMed/NCBI
35	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
36	Lerner UH, Kindstedt E and Lundberg P: The critical interplay between bone resorbing and bone forming cells. J Clin Periodontol. 46 (Suppl 21):33–51. 2019. View Article : Google Scholar : PubMed/NCBI
37	Fili S, Karalaki M and Schaller B: Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. Cancer Lett. 283:10–19. 2009. View Article : Google Scholar : PubMed/NCBI
38	Kearns AE, Khosla S and Kostenuik PJ: Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 29:155–192. 2008. View Article : Google Scholar : PubMed/NCBI
39	Horowitz MC, Xi Y, Wilson K and Kacena MA: Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev. 12:9–18. 2001. View Article : Google Scholar : PubMed/NCBI
40	Wada T, Nakashima T, Hiroshi N and Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 12:17–25. 2006. View Article : Google Scholar : PubMed/NCBI
41	Long F: Building strong bones: Molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 13:27–38. 2011. View Article : Google Scholar : PubMed/NCBI
42	Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, Mizoguchi T, Sato M, Mogi M, Penninger JM and Takahashi N: Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol. 178:192–200. 2007. View Article : Google Scholar : PubMed/NCBI
43	Valenti MT, Dalle Carbonare L and Mottes M: Osteogenic differentiation in healthy and pathological conditions. Int J Mol Sci. 18:412016. View Article : Google Scholar : PubMed/NCBI
44	Wan Hasan WN, Abd Ghafar N, Chin KY and Ima-Nirwana S: Annatto-derived tocotrienol stimulates osteogenic activity in preosteoblastic MC3T3-E1 cells: A temporal sequential study. Drug Des Devel Ther. 12:1715–1726. 2018. View Article : Google Scholar : PubMed/NCBI
45	Czekanska EM, Stoddart MJ, Richards RG and Hayes JS: In search of an osteoblast cell model for in vitro research. Eur Cell Mater. 24:1–17. 2012. View Article : Google Scholar : PubMed/NCBI
46	Aubin JE: Regulation of osteoblast formation and function. Rev Endocr Metab Disord. 2:81–94. 2001. View Article : Google Scholar : PubMed/NCBI
47	Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I and Cortet B: Influence of Adipokines and Ghrelin on Bone Mineral Density and Fracture Risk: A systematic review and meta-analysis. J Clin Endocrinol Metab. 96:2703–2713. 2011. View Article : Google Scholar : PubMed/NCBI
48	Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD and Liao EY: Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 21:1648–1656. 2006. View Article : Google Scholar : PubMed/NCBI
49	Wang QP, Li XP, Wang M, Zhao LL, Li H, Xie H and Lu ZY: Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: An in vivo study. Endocrine. 47:845–853. 2014. View Article : Google Scholar : PubMed/NCBI
50	Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP and Liao EY: Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 309:99–109. 2005. View Article : Google Scholar : PubMed/NCBI
51	Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H and Shimomura I: Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 331:520–526. 2005. View Article : Google Scholar : PubMed/NCBI
52	Wu SS, Liang QH, Liu Y, Cui RR, Yuan LQ and Liao EY: Omentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathway. Int J Endocrinol. 2013:3689702013. View Article : Google Scholar : PubMed/NCBI
53	Miyazono K: TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev. 11:15–22. 2000. View Article : Google Scholar : PubMed/NCBI
54	ten Dijke P, Miyazono K and Heldin CH: Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem Sci. 25:64–70. 2000. View Article : Google Scholar : PubMed/NCBI
55	van Zoelen EJ, Duarte I, Hendriks JM and van der Woning SP: TGFβ-induced switch from adipogenic to osteogenic differentiation of human mesenchymal stem cells: Identification of drug targets for prevention of fat cell differentiation. Stem Cell Res Ther. 7:1232016. View Article : Google Scholar : PubMed/NCBI
56	Santibanez JF and Kocic J: Transforming growth factor-β superfamily, implications in development and differentiation of stem cells. Biomol Concepts. 3:429–445. 2012. View Article : Google Scholar : PubMed/NCBI
57	Petruschke T, Röhrig K and Hauner H: Transforming growth factor beta (TGF-beta) inhibits the differentiation of human adipocyte precursor cells in primary culture. Int J Obes Relat Metab Disord. 18:532–536. 1994.PubMed/NCBI
58	Choy L, Skillington J and Derynck R: Roles of autocrine TGF-beta receptor and Smad signaling in adipocyte differentiation. J Cell Biol. 149:667–682. 2000. View Article : Google Scholar : PubMed/NCBI
59	El Bialy I, Jiskoot W and Reza Nejadnik M: Formulation, delivery and stability of bone morphogenetic proteins for effective bone regeneration. Pharm Res. 34:1152–1170. 2017. View Article : Google Scholar : PubMed/NCBI
60	Rutkovskiy A, Stensløkken KO and Vaage IJ: Osteoblast differentiation at a glance. Med Sci Monit Basic Res. 22:95–106. 2016. View Article : Google Scholar : PubMed/NCBI
61	Yang D, Okamura H and Qiu L: Upregulated osterix expression elicited by Runx2 and Dlx5 is required for the accelerated osteoblast differentiation in PP2A Cα-knockdown cells. Cell Biol Int. 42:403–410. 2018. View Article : Google Scholar : PubMed/NCBI
62	Komori T: Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem Cell Biol. 149:313–323. 2018. View Article : Google Scholar : PubMed/NCBI
63	Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, et al: Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell. 89:773–779. 1997. View Article : Google Scholar : PubMed/NCBI
64	Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR and de Crombrugghe B: The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 108:17–29. 2002. View Article : Google Scholar : PubMed/NCBI
65	Varma S, Orgel JP and Schieber JD: Nanomechanics of type I collagen. Biophys J. 111:50–56. 2016. View Article : Google Scholar : PubMed/NCBI
66	Murshed M: Mechanism of bone mineralization. Cold Spring Harb Perspect Med. 8:a0312292018. View Article : Google Scholar : PubMed/NCBI
67	Kisling A, Lust RM and Katwa LC: What is the role of peptide fragments of collagen I and IV in health and disease? Life Sci. 228:30–34. 2019. View Article : Google Scholar : PubMed/NCBI
68	Chen Y, Ou Y, Dong J, Yang G, Zeng Z, Liu Y, Liu B, Li W, He X and Lan T: Osteopontin promotes collagen I synthesis in hepatic stellate cells by miRNA-129-5p inhibition. Exp Cell Res. 362:343–348. 2018. View Article : Google Scholar : PubMed/NCBI
69	An J, Yang H, Zhang Q, Liu C, Zhao J, Zhang L and Chen B: Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci. 147:46–58. 2016. View Article : Google Scholar : PubMed/NCBI
70	Zhou H, Choong P, McCarthy R, Chou ST, Martin TJ and Ng KW: In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res. 9:1489–1499. 1994. View Article : Google Scholar : PubMed/NCBI
71	van Leeuwen JP, van Driel M, van den Bemd GJ and Pols HA: Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr. 11:199–226. 2001.PubMed/NCBI
72	Takahashi T, Kato S, Suzuki N, Kawabata N and Takagi M: Autoregulatory mechanism of Runx2 through the expression of transcription factors and bone matrix proteins in multipotential mesenchymal cell line, ROB-C26. J Oral Sci. 47:199–207. 2005. View Article : Google Scholar : PubMed/NCBI